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ABSTRACT: The development of small molecule activity-
based probes (ABPs) is an evolving and powerful area of
chemistry. There is a major need for synthetically accessible
and speciﬁc ABPs to advance our understanding of enzymes in
health and disease. α-Glucosidases are involved in diverse
physiological processes including carbohydrate assimilation in
the gastrointestinal tract, glycoprotein processing in the
endoplasmic reticulum (ER), and intralysosomal glycogen
catabolism. Inherited deﬁciency of the lysosomal acid α-
glucosidase (GAA) causes the lysosomal glycogen storage disorder, Pompe disease. Here, we design a synthetic route for
ﬂuorescent and biotin-modiﬁed ABPs for in vitro and in situ monitoring of α-glucosidases. We show, through mass spectrometry,
gel electrophoresis, and X-ray crystallography, that α-glucopyranose conﬁgured cyclophellitol aziridines label distinct retaining α-
glucosidases including GAA and ER α-glucosidase II, and that this labeling can be tuned by pH. We illustrate a direct diagnostic
application in Pompe disease patient cells, and discuss how the probes may be further exploited for diverse applications.
■ INTRODUCTION
Lysosomal α-glucosidase (GAA, α-1,4-glucosidase, acid mal-
tase) (E.C. 3.2.1.20) is a retaining α-glucosidase, which has
been classiﬁed into CAZy family GH31.1−4 Following
processing within endoplasmic reticulum the 110 kDa (952
AA) precursor is transported to the lysosomes, where it is
modiﬁed to active 76 and 70 kDa isoforms.5,6 Within the
lysosomes, GAA catalyzes the degradation of glycogen via a
general acid/base catalyzed double displacement mechanism,7,8
releasing a molecule of α-glucose with net retention of
stereochemistry at its anomeric center (Figure 1a). Deﬁciency
in GAA leads to the glycogen storage disease type II, known as
Pompe disease.9 In Pompe patients, intralysosomal glycogen
accumulation causes progressive muscle weakness in heart and
skeletal muscles and also aﬀects the liver and nervous system.10
Diﬀerent clinical forms of Pompe disease are usually discerned
based on age of onset. The infantile-onset form manifests at 4
to 8 months and, when untreated, results in death in the ﬁrst
years of life.11 Later onset forms generally progress more slowly
and are characterized by progressive decrease in muscle
strength in the legs followed by smaller muscles in the trunk
and arms and ultimately to fatality through respiratory failure.12
The severity of the Pompe disease and its progress correlates
with the extent of enzyme loss. Pompe disease is currently
treated by chronic intravenous administration of recombinant
human GAA (rGAA, alglucosidase alfa; Myozyme). Impressive
delay of fatal symptoms by enzyme replacement therapy (ERT)
is observed in infantile Pompe disease patients,13 but treatment
of late onset disease requires very large amounts of therapeutic
enzyme due to poor correction of muscle cell pathology.14
The identiﬁcation of GAA activity in living cells or tissues is
challenging. We have previously shown that activity-based
protein proﬁling (ABPP) is an eﬀective methodology to
quantify β-glucosidases responsible for the lysosomal storage
disorder, Gaucher disease.15,16 Linking “reporter moieties” to
the aziridine nitrogen in the retaining β-glucosidase inhibitor,
cyclophellitol aziridine, yielded in-class broad-spectrum retain-
ing β-glucosidase probes. These probes label, besides lysosomal
glucosylceramidase (GBA-the enzyme deﬁcient in Gaucher
disease), also neutral glucosylceramidase (GBA2), broad-
speciﬁcity β-glucosidase (GBA3), and lactase phloridzin
hydrolase (LPH).16−21 Based on these ﬁndings we hypothe-
sized that the corresponding α-glucopyranose conﬁgured,
nitrogen-substituted cyclophellitol aziridines (Figure 1b)
would be eﬀective ABPs for speciﬁc labeling of GH31 retaining
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α-glucosidases, besides GAA also ER α-glucosidase II (GANAB,
a crucial enzyme in the quality control of newly formed
glycoproteins in the ER) and intestinal α-glucosidases involved
in food processing. Here we report the successful development
of such in-class GH31 α-glucosidase ABPs. We demonstrate
covalent labeling by mass spectrometry and X-ray crystallog-
raphy of a representative bacterial GH31 enzyme homologous
to GAA. We reveal that α-glucosidases are labeled in situ by our
ABPs and that the absence of GAA in Pompe disease cells is
readily demonstrated in a diagnostic manner.
■ RESULTS
Synthesis of Mechanism-Based Inhibitors and Activ-
ity-Based Probes. As the ﬁrst research objective we set out to
develop an eﬃcient route of synthesis for the preparation of α-
conﬁgured cyclophellitol aziridine 1 (Figure 2). During our
previous work on retaining β-glucosidase probes we developed
an optimized route toward cyclohexene 8, the precursor in the
total synthesis, by Madsen and co-workers, of the natural
product and retaining β-glucosidase inhibitor, cyclophellitol.22
We reasoned that an iodocyclization scheme, with an
appropriate nitrogen nucleophile delivered to the alkene-
derived iodonium ion from the allylic alcohol position, would
yield an appropriately conﬁgured 2-amino-1-iodo species for
subsequent intramolecular cyclization in a stereospeciﬁc
fashion. For this purpose, the benzyl protective groups in 8
were removed by Birch reduction, after which the 4,6-
benzylidene (glucopyranose numbering) was installed to give
9. The allylic alcohol in 9 proved the most reactive of the two
secondary alcohols toward trichloroacetonitrile in the presence
of 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) as the catalytic
base, providing imidate 10 as the major product in the presence
of small amounts of the bis-imidate. Subsequent key
iodocyclization aﬀorded in a stereospeciﬁc fashion cyclic
imidate 11. Both cyclic imidate and benzylidene acetal were
hydrolyzed under acidic conditions, and the resulting crude
primary amine 12 was treated with sodium bicarbonate giving
aziridine 1. The aziridine nitrogen in 1 was alkylated with 1-
iodo-7-azidoheptane to yield 2, onto which and by means of
copper(I)-catalyzed azide−alkyne [2 + 3] cycloaddition either a
BODIPY-green dye, a BODIPY-red dye, a Cy5 dye, or a biotin
was conjugated, to give ABPs 3, 4, 5 and 6, respectively (Figure
2). 1,6-epi-Cyclophellitol 7 was prepared by stereoselective
epoxidation of 9 with 3-chloroperbenzoic acid (mCPBA) and
deprotection of benzylidene acetal group of the resulting 17 by
Pearlman’s catalyst hydrogenation. As reference competitive
inhibitors, we used deoxynojirimycin derivatives 18−22 and
maltose 23 (Figure S1).23
In Vitro Inhibition and Labeling of Recombinant
Human GAA. We ﬁrst tested the inhibitory properties of
compounds 1−7 (Figure 2) toward rGAA (Myozyme,
Genzyme) at pH 4.0 using 4-methylumbelliferyl-α-glucose as
substrate (Figure 3a). All compounds proved to be potent
rGAA inhibitors with apparent IC50 values in the nanomolar
range. The most potent inhibitor of the series is cyclophellitol
aziridine 1, with epoxide 7 and N-alkyl aziridine 2 within the
same range, albeit slightly weaker (Figure 3a). Fluorescent
ABPs 3−5 all showed about 10-fold increased apparent IC50
Figure 1. The mechanism of action of retaining α-glucosidases allows the development of activity-based probes. (a) Koshland double-displacement
mechanism employed by retaining α-glucosidases. (b) α-Glucose-conﬁgured N-alkyl cyclophellitol aziridines as mechanism-based irreversible
retaining α-glucosidase inhibitors (1, 2) and probes (3−6).
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values compared to 1, and biotin-conjugated ABP 6 a further 2-
fold increase. In situ enzyme inhibition within human ﬁbroblasts
exhibited similar potency, except for biotin compound 6 (IC50
> 10 μM), which apparently is the least cell-permeable of the
series. The pH optimum of 5.0 found for labeling of 110 kDa
rGAA diﬀered slightly from that of enzymatic activity toward
4MU-α-glucose pH 4.0 (Figure 3b). When rGAA was
preincubated for 30 min with 10 μM 1, 2, and 4−7, followed
by labeling with compound 3, green ﬂuorescent labeling of
rGAA by compound 3 was abrogated (Figure 3c). Likewise, the
presence of high concentrations of the substrates 4MU-α-
glucose and maltose reduced labeling by compound 3 as does
prior denaturation of rGAA by incubation with 2% SDS.
Inhibitors 1−7 reacted too fast for kinetics analysis: for
instance, time dependent labeling of rGAA by 100 nM ABP 3 at
4 and 37 °C demonstrated that most of the enzyme could be
labeled within 2 min (Figure S2a).
To establish the mechanism-based mode of action of our
probes, we took advantage of a bacterial homologue of GAA
from CAZy family GH31, the α-glucosidase from Cellvibrio
japonicus, CjAgd31B, which is readily amenable to structure
studies of GH31 ligand complexes and displays 27% identity to
the human GAA enzyme over 615 amino acids including
absolute conservation of the active center “-1” glucosyl site.24
The 1.95 Å resolution structure of CjAgd31B (Figure 3d)
soaked with cyclophellitol aziridine 2 revealed unambiguous
electron density showing covalent binding of the ring opened
cyclophellitol aziridine β-linked to the active site nucleophile
residue (Asp412; equating to Asp518 of GAA and Asp542 of
GANAB). Apart from demonstrating irrevocably the mecha-
nism-based mode of action of our probes, the GH31 complex
with 2 is consistent with the reaction pathway employed by
GH31 in processing α-glucosidic linkages. Substrates are
proposed to bind in a 4C1 conformation with catalysis occurring
via a 4H3 oxacarbenium ion like transition state to a covalent
adduct in 1S3 skew-boat conformation.
25,26 This 1S3 con-
formation of the enzyme−inhibitor adduct is well captured in
the complex shown in Figure 3d. Similarly, the 1S3
conformation of the enzyme−inhibitor 1 adduct was also well
captured in 1.85 Å resolution (Figure S2b).
ABP Labeling of Multiple α-Glucosidases in Homoge-
nates of Fibroblasts. Having established the expected
covalent inactivation we next examined ABP labeling of α-
glucosidases in a more complex and physiologically relevant
Figure 2. Synthesis of the cyclophellitol aziridine inhibitors 1, 2, probes 3−6 and 1,6-epi-cyclophellitol 7. Reagents and conditions: (a) (i) Li, NH3,
THF, −60 °C, 57%; (ii) PhCH(OMe)2, CSA, DMF, 61%. (b) CCl3CN, DBU, DCM, 0 °C. (c) NaHCO3, I2, H2O, two step yield 41%. (d) 37% HCl
aq, dioxane. (e) NaHCO3, MeOH, two step yield 63%. (f) 1-Azido-8-iodooctane, K2CO3, DMF, 80 °C, 39%. (g) 13, 14, 15, or 16, CuSO4, sodium
ascorbate, DMF, 38% 3, 11% 4, 24% 5, 23% 6. (h) mCPBA, DCM, 40 °C, 44%. (i) Pd(OH)2/C, H2, MeOH, 68%.
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biological mixture of proteins. For this, we prepared
homogenates of cultured ﬁbroblasts and exposed these to 1
μM ABP 5 at various pH values. Incubation with ABP 5 at pH
4.0 gave clean labeling of what appeared to be the mature
lysosomal forms of GAA (two bands at around 70 kDa). At
higher pH values an additional protein with a molecular weight
of around 100 kDa was observed (Figure 4a). GAA precursor
amounts are low in cells and areas with the mature form
optimally active at low pH. We therefore thought it unlikely
that the protein labeled at 100 kDa would be the GAA pro-
form. Rather, we envisaged that this band would correspond to
another α-glucosidase, possibly ER α-glucosidase II. To
establish, unambiguously, the nature of the 70 kDa proteins
identiﬁed at acidic pH as well as the 100 kDa protein seen at
neutral pH, we used aﬃnity puriﬁcation and chemical
proteomics of ﬁbroblast homogenates treated with biotin-
conjugated ABP 6. A lysate of ﬁbroblasts was incubated at pH
4.0 and pH 7.0 with ABP 6, in either the presence or absence of
pretreated ABP 3. Next, biotinylated proteins were enriched by
pull-down using streptavidin-coated magnetic beads. Loaded
streptavidin beads were split for in-gel digestion and on-bead
digestion. Captured proteins for subsequent in-gel digestion
were released in Laemmli buﬀer, resolved on SDS−PAGE and
visualized by silver staining (Figure 4b). Three distinct bands
Figure 3. In vitro inhibition and labeling of α-glucosidases. (a) Inhibition of recombinant GAA. Apparent IC50 values (extrapolated with one phase
exponential association) are the mean of three separate experiments. Error ranges depict standard deviation. (b) Labeling of rGAA with compound 3
at various pH values as compared to activity toward 4-MU-α-D-glucopyranose. Error bars represent standard deviation. (c) ABP labeling of rGAA
with 3 competed with compounds 1, 2, and 4−7. (d) Stereoscopic view of the CjAgd31B active site in complex with compound 2, showing covalent
link to CjAgd31B enzymatic nucleophile Asp412, and H-bonding interactions to neighboring residues. Electron density is REFMAC maximum-
likelihood/σA-weighted 2 Fo − Fc synthesis contoured at 0.49 electrons per Å3.
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were obtained that all could be competed for by inclusion of α-
cyclophellitol aziridine 3. Two bands with apparent molecular
masses of around 70 kDa are most prominent in the pull-down
at pH 4.0, and one band at approximately 100 kDa was the
predominant species labeled at pH 7.0. Tryptic digestion was
performed on these three protein bands, and the resulting
tryptic peptides were analyzed by nanoscale liquid chromatog-
raphy coupled to tandem mass spectrometry (nano-LCMS/
MS). The proteins were identiﬁed via matching of the obtained
peptide sequences against the Mascot database. In this manner,
the ∼70 kDa proteins were identiﬁed as the two mature forms
(70 and 76 kDa) of GAA (Figure 4c). The labeled 100 kDa
protein proved to be GANAB and isoform 2 of GANAB, the
known retaining ER α-glucosidase II (Figure 4c).
Using on-bead trypsin digestion very similar results were
obtained. GAA in the pH 4.0 incubation and GANAB in the pH
7.0 incubation topped the exponentially modiﬁed protein
abundance index (emPAI), a relative quantitation of the
proteins in a mixture based on protein coverage by the peptide
matches in a database search result, and protein scores from
Mascot search report (Figure 4d and Figure S3). Comparable
experiments with mouse liver lysates (Figures S4, S5) resulted
in identiﬁcation of GAA and GANAB as the major targets of
biotin-aziridine ABP 6, matching the ﬂuorescent bands on
SDS−PAGE. Using a ﬁnal concentration of 10 μM of biotin-
aziridine 6 in the aﬃnity puriﬁcation experiments, we also
observed enrichment of a protein with apparent molecular mass
of 60−65 kDa (Figure S4). Proteomics analysis identiﬁed this
protein as GBA, the lysosomal acid β-glucosidase deﬁcient in
Gaucher disease. To corroborate this observation we
determined possible inhibition of enzymatic activity of pure
GBA by compounds 1−7. Indeed, GBA is also inhibited by all
of the prepared compounds with apparent IC50 values in the
range of 592.8 nM to 155.3 μM (Table S1). For comparison,
the corresponding β-conﬁgured cyclophellitol aziridine
JJB34315 was a far more potent inhibitor toward GBA with
500-fold lower apparent IC50 values than α-aziridine 4 JJB347
in the same test.
Labeling of α-Glucosidases Present in Murine Gastro-
intestinal Tracts. Given the observed high aﬃnity labeling
with our ABPs of both GAA and GANAB, we next examined
labeling of proteins in extracts from intestines, tissue known to
Figure 4. Labeling of multiple α-glucosidases and their identiﬁcation by proteomics. (a) Labeling of proteins in ﬁbroblast lysate with compound 5.
(b) Workﬂow of pull-down proteomics experiments. (c) In-gel digestion silver staining and identiﬁcation of target proteins modiﬁed by biotin-ABP
6. (d) Glycosidase identiﬁcation with Mascot score and emPAI values after on-bead pull-down and processing of ﬁbroblast lysate with biotin-ABP 6.
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contain additional retaining GH31 α-glucosidases. For this
purpose, mouse intestine was freshly collected, food remains
and bacteria were removed by rinsing, and the tissue was lysed
in KPi-Triton buﬀer using sonication. The lysate was incubated
with biotinylated compound 6, and bound proteins were
analyzed by gel electrophoresis and chemical proteomics as
before (Figures S6, S7). In this way we observed, in addition to
biotin-ABP 6 labeling of GAA and GANAB, labeling of sucrase-
isomaltase (Sis) and maltase-glycoamylase (MGAM), two
retaining α-glucosidases expressed speciﬁcally in intestinal
tissue. In addition, the retaining β-glucosidases, lactase (Lct)
and GBA, were identiﬁed. The ﬁndings were recapitulated by
labeling lysates of pull-down and supernatant samples with
ABPs 3 and 6, protein separation by gel electrophoresis, and
ﬂuorescence imaging of the wet gel slabs, followed by
transferring protein to polyvinylidene ﬂuoride (PVDF)
membrane for Western blot analysis with HRP-streptavidin.
Fluorescent bands, chemiluminescence bands, and silver stain
protein bands matched well, and the expected molecular masses
for GAA, GANAB, Sis, MGAM, Lct, and GBA were observed
(Figure S6).
Labeling and Concomitant Inhibition of α-Glucosi-
dases in Intact Cells. Prompted by the eﬀective in vitro
labeling of GH31 α-glucosidases in cell and tissue extracts, we
studied the labeling of enzymes in intact cultured ﬁbroblasts
with ABPs 3 and 5. Fibroblasts were exposed to 100 nM ABP 5
for various times (from 10 min to 4 h) by including these in the
culture medium. Subsequently, cells were extensively washed
and harvested, and lysates were prepared at 4 °C and then
separated by SDS−PAGE followed by ﬂuorescence scanning of
Figure 5. In situ labeling of GAA and GANAB in living ﬁbroblasts. (a) Time-dependent labeling of GAA and GANAB in ﬁbroblasts by ABP 5 in situ
and ABP 3 in vitro. (b) Chloroquine blocks in situ GAA labeling.
Figure 6. In vitro ABP labeling and Western blot detection of α-glucosidases in wild type and Pompe ﬁbroblasts. (a). In vitro GAA labeling at pH 4.0
with 3, followed by Western blot detection of GAA in various ﬁbroblast lysates, containing wild type or mutant (Pompe) GAA. (b). In vitro GANAB
labeling at pH 7.0 with 3 followed by Western blot detection of GAA in various ﬁbroblast lysates, containing wild type or mutant (Pompe) GAA.
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the wet gel slabs (Figure 5a left). Fluorescent labeling of GAA
and GANAB was prominent in blue bands. Of note, no GBA
was concomitantly labeled in situ, illustrating the far lower
aﬃnity of the α-glucopyranose ABP to label this β-glucosidase,
but GBA was labeled by excess of ABP 3 under in vitro
conditions (Figure 5a right). We added during the procedure
an excess of ABP 3 to exclude artiﬁcial labeling of enzymes by
nonreacted free ABP 5 during the process of cell lysis. This
addition did not change the result, demonstrating that labeling
of GAA and GANAB truly occurs in situ.
GAA requires an acid pH for labeling by the α-glucopyranose
ABP (Figure 3a). We therefore investigated the eﬀect of
chloroquine, an agent that raises intralysosomal pH.27
Fibroblasts were incubated with either increasing amount of
chloroquine (10, 25, and 50 μM) for 3 h or increasing
treatment time (1, 2, and 3 h), after which ABP 5 was added to
the medium. After the time points, cells were washed,
harvested, and analyzed on labeled protein. As shown in Figure
5b, the presence of chloroquine abolished in situ labeling of
GAA but not GANAB.
Diagnostic Application: Probing for GAA Activity in
Pompe Disease Patient Material. Finally, we studied the
value of our ABPs for diagnosis of Pompe disease. Fibroblasts
of normal individuals and Pompe disease patients suﬀering
from the infantile and adult variants of disease were cultured.
Cell lysates were labeled with 0.5 μM of ABP 3 for 30 min at
pH 4.0 and pH 7.0. Gel electrophoresis of the denatured
protein content and subsequent ﬂuorescence imaging and
immunoblots revealed a prominent distinction between ma-
terial from normal persons and Pompe disease patients (Figure
6 and Figure S8). Marked absence of ﬂuorescently labeled
mature 70/76 kDa GAA with concomitant normal levels of
GANAB was only observed for the patient ﬁbroblasts. This
ﬁnding demonstrates the potential of our α-glucosidase ABPs in
laboratory diagnosis of Pompe disease.
■ DISCUSSION
Activity-based protein proﬁling (ABPP) has emerged in the
past 15 years as a powerful technique to identify enzymes and
to study their activity in the context of the physiological
processes they partake in, both in vitro and in situ. In the ﬁrst
instance developed for serine hydrolases and cysteine
proteases,28,29 ABPs can on paper be designed for any enzyme,
provided that a covalent enzyme−substrate adduct emerges
during enzyme action. Retaining glycosidases that employ a
Koshland two-step double displacement mechanism fulﬁll this
requirement, and we have reported previously on the versatility
of the natural product, cyclophellitol, as a scaﬀold for activity-
based glycosidase probe design. In this work, we capitalize on
this generic design principle by the development of a set of α-
conﬁgured cyclophellitol aziridines as in-class GH31 retaining
α-glucosidase ABPs. Our probes label GH31 retaining α-
glucosidases in a tissue-dependent fashion and allow detection
and identiﬁcation of these by in-gel ﬂuorescence, by cell
imaging, and by chemical proteomics. They are highly selective
toward GH31 retaining α-glucosidases when applied in the
appropriate concentration and even at higher concentrations
show little to no cross-reactivity, apart from labeling the
retaining β-glucosidase, GBA. The ABPs label subcellular α-
glucosidases optimally at the pH at which the α-glucosidases
display maximal enzymatic activity. Thus, whereas GAA in
ﬁbroblasts is maximally labeled at pH 4.0−5.0, GANAB, or ER-
α-glucosidase II, is optimally labeled at neutral pH. This ﬁnding
underscores that our probes report on functional enzymes,
rather than protein levels, an observation that is corroborated
by the X-ray structure we obtained of CjAgd31B rGAA, in
which ABP precursor 2 has reacted with the active site
nucleophile, Asp412.
The tissue-speciﬁc and pH-dependent mode of action of our
ABPs allows for probing each of the targeted α-glucosidases
independently and within their physiological context, as well as
in health and disease. The diagnostic value of our probes is
demonstrated in the assessment of the lack of GAA activity in
infantile and adult Pompe disease tissue (Figure 6 and Figure
S8). Our in-class broad-spectrum GH31 α-glucosidase probes
may also ﬁnd use in the discovery of inhibitors speciﬁc for
either GAA or GANAB in a competitive ABPP assay. Selective
inhibitors for GAA or GANAB would be of interest: GAA
inhibitors for pharmacological chaperone discovery in the
context of Pompe disease and GANAB inhibitors for antiviral
or anticancer drug discovery (GANAB activity being a crucial
factor in the quality control of nascent N-linked glycoproteins).
We performed an initial competitive ABPP in which ﬁbroblasts
expressing GAA and GANAB were ﬁrst treated with varying
concentrations of the iminosugars 18−22 and maltose 23
followed by incubation at both pH 4.0 and pH 7.0 with ABP 5.
As can be seen in Figure S9, these compounds eﬃciently inhibit
both enzymes. Indeed no selective inhibitors for either enzyme
are known, and our ABPs may be of help in identifying such
compounds. Our ABPs ﬁnally also eﬃciently target and identify
intestinal α-glucosidases, which are key players in glucose
assimilation and the targets of the antidiabetic drugs, miglitol
and acarbose. The ability to also study these intestinal enzymes
in detail in their physiological surroundings holds promise for
the future identiﬁcation of more eﬀective (and selective with
respect to GAA/GANAB inhibition) inhibitors, which may
come from natural sources and become part of nutraceutical
regimes.
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